Medicilon IncMedicilon IncMedicilon IncMedicilon Inc
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthesis Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Bioanalytical Services
      • Large Molecule Services
      • Small Molecule Services
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
    • Integrated Projects
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Our Events
    • Market Activity
    • Press Events
  • Contact

Therapeutic Vaccine Suppresses Peanut Allergies

Home Press Events
NextPrevious

Therapeutic Vaccine Suppresses Peanut Allergies

By medicilon | Press Events | 12 April, 2018 |

In recent years, the number of nut allergies has skyrocketed. While the theories behind the specific origins for this spike are numerous and often controversial, the physiological effects are real and for many, potentially life-threatening. Due to the real need for clinical intervention, many researchers have been on the hunt to develop therapies that can prevent detrimental issues before they begin. Now, investigators from the Mary H. Weiser Food Allergy Center at the University of Michigan have released new findings that show that a therapeutic vaccine may successfully turn off peanut allergy in mice.

 

Findings from the new study – published in the Journal of Allergy and Clinical Immunology through an article entitled “Nanoemulsion adjuvant–driven redirection of TH2 immunity inhibits allergic reactions in murine models of peanut allergy” showed that just three monthly doses of a nasal vaccine protected the mice from allergic reactions upon exposure to peanuts. Moreover, immunizing peanut allergic mice can redirect how immune cells responded to peanuts in allergic mice. This novel approach activates a different type of immune response that prevents allergic symptoms.

“We’re changing the way the immune cells respond upon exposure to allergens,” explained lead study author Jessica O’Konek, Ph.D., a research investigator at the food allergy center. “Importantly, we can do this after an allergy is established, which provides for potential therapy of allergies in humans. By re-directing the immune responses, our vaccine not only suppresses the response but prevents the activation of cells that would initiate allergic reactions.”

 

In the current study, the mouse models responded to peanut allergies similarly to affected humans, with symptoms that included itchy skin and trouble breathing. The study assessed protection from allergic reactions two weeks after the final dose of vaccine was administered. Studies to determine the duration of protection are ongoing, but researchers are encouraged that this approach could lead to long-lasting suppression of allergies.

 

“The NE intranasal immunizations resulted in marked decreases in TH2 cytokine, IgG1, and IgE levels, whereas TH1 and mucosal TH17 immune responses were increased,” the authors wrote. “After allergen challenge, these mice showed significant reductions in allergic hypersensitivity. Additionally, the NE immunizations significantly increased antigen-specific IL-10 production and regulatory T-cell counts, and the protection induced by NE was dependent in part on IL-10. Control animals immunized with intranasal peanut in saline had no modulation of their allergic response.”

 

The findings are another step toward a potential clinical trial down the road to test the method in humans. The next steps include further studies in mice to better understand the mechanisms responsible for the suppression of food allergies and learn whether protection from peanut allergies can be extended for an even longer period.

 

“Right now, the only FDA approved way to address food allergy is to avoid the food or suppress allergic reactions after they have already started,” Dr. O’Konek noted. “Our goal is to use immunotherapy to change the immune system’s response by developing a therapeutic vaccine for food allergies.”

 

“Food allergy has exploded in prevalence and incidence, but we still know so little about it because there hasn’t been that much research in the field,” added senior study investigator James Baker Jr., M.D., director of the U-M Mary H. Weiser Food Allergy Center and who is also the CEO of Food Allergy Research and Education (FARE).

 

“This research is also teaching us more about how food allergies develop and the science behind what needs to change in the immune system to treat them,” Dr. Baker concluded.

No tags.

Related Post

  • Novel Research Model Offers Hope to ALS and MS Patients

    Scientists at the Karolinska Institute in Sweden have developed a new disease model for neurodegenerative disordersRead more

  • Human Brain Organoids Thrive in Mouse Brains

    Brain organoids, also known as mini-brains, are tiny clumps of brain cells grown from stem cellsRead more

  • Mitochondria Choked with Proteins Can Activate Gag Reflex

    When the cell tries to stuff too many proteins into its mitochondria, protein blockages and backupsRead more

  • Blood Pressure Drugs Work Best with Musical Accompaniment

    Listening to music heightens the beneficial effects of blood pressure–lowering drugs, according to the results ofRead more

  • Soluble Antibodies Play Immune Suppressive Role in Tumor Progression

    Scientists at the Wistar Institute have found that soluble antibodies promote tumor progression by inducing accumulationRead more

  • CRISPR Combines with Gene Delivery System to Create Brain Tumor Model

    In animal models, disease recapitulation is the guiding principle. Scientists spend considerable time and effort tryingRead more

  • “Sweet Tooth” Gene Variant Associated with Lower Body Fat

    A common variant of the gene for the liver hormone fibroblast growth factor 21 (FGF21) geneticallyRead more

  • Personalized Cancer Vaccine Shows Promise in Patients with Advanced Ovarian Cancer

    Ovarian cancer is a particularly hard-to-treat disease. It’s often diagnosed late, and even after surgery andRead more

NextPrevious

News

  • Our Events
  • Market Activity
  • Press Events

Top Posts

  • 14 October, 2016

    Preclinical Drug Development Process

  • 14 February, 2017

    IND Enabling Studies FDA

  • 7 February, 2017

    Target Identification and Validation in Drug Discovery

  • 15 February, 2017

    Drug Discovery and Development Services

Share

About Us

  • Medicilon Overview
  • Executive Team
  • CEO Message
  • Company History
  • Corporate Culture
  • Honor

Services

  • Chemistry Services
  • Biology Services
  • Bioanalytical Services
  • Drug Safety Evaluation
  • Formulation Development Services
  • Pharmacology Services
  • Pharmacokinetic Services
  • Integrated Projects

Customer Center

  • Customer Reviews
  • Download Center
  • Intellectual Property Protection
  • New Models of Collaboration

Contact Us

Shanghai Medicilon Inc.
Email: Marketing@medicilon.com.cn
Website: www.medicilon.com

Copyright 2017 Shanghai Medicilon inc. | All Rights Reserved
  • Languages
  • 中国日本대한민국
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthesis Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Bioanalytical Services
      • Large Molecule Services
      • Small Molecule Services
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
    • Integrated Projects
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Our Events
    • Market Activity
    • Press Events
  • Contact
Medicilon Inc